Company research
Perspective Therapeutics, Inc.
CIK 728387Updated Nov 19, 2026
CATX price & chart
Loading TradingView…
AMEX:CATX on TradingView ↗About the company
Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced systemic treatments for cancers. The Company has proprietary technology that utilizes the alpha-generating isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, creating an opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.
In the news
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors ↗
Recent filings
SCHEDULE 13G/A - filed by Commodore Capital LP regarding Perspective Therapeutics, Inc.
SCHEDULE 13G - filed by STATE STREET CORP regarding Perspective Therapeutics, Inc.
10-Q filing
Results of Operations and Financial Condition · Other Events
Items 2.02, 8.01, 9.01
Other Events
Items 8.01, 9.01
Show 5 more recent filings
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
SCHEDULE 13D/A - filed by Lantheus Holdings, Inc. regarding Perspective Therapeutics, Inc.
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 | Q1 2023 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | — | — | — | 266,972,000Source | 341,101,000Source | 97,891,000Source | 58,091,000Source | 62,538,000Source | 266,972,000Source | 341,101,000Source | 97,891,000Source | 64,439,000Source |
| Property, Plant and Equipment, NetUSD | — | — | — | 76,597,000Source | 57,321,000Source | 5,576,000Source | 1,684,000Source | 1,999,000Source | 76,597,000Source | 57,321,000Source | 5,576,000Source | 1,976,000Source |
| GoodwillUSD | — | — | — | — | — | 24,062,000Source | 0Source | — | — | 0Source | 24,062,000Source | — |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | — | — | — | 0Source | — | 362,000Source | 279,000Source | 354,000Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | — | 30,629,000Source | 61,580,000Source | 9,238,000Source | 20,993,000Source | 18,989,000Source | 30,629,000Source | 61,580,000Source | 9,238,000Source | 55,890,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | 6,000Source | 116,000Source | 1,165,000Source | 1,363,000Source | — | 6,000Source | 116,000Source | 1,165,000Source | — |
| Inventory, NetUSD | — | — | — | — | — | — | 1,409,000Source | 1,553,000Source | — | — | — | 1,396,000Source |
| Assets, CurrentUSD | — | — | — | 148,389,000Source | 231,160,000Source | 16,837,000Source | 53,215,000Source | 57,540,000Source | 148,389,000Source | 231,160,000Source | 16,837,000Source | 59,329,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | — | — | 3,646,000Source | 4,128,000Source | 1,133,000Source | 577,000Source | 662,000Source | 3,646,000Source | 4,128,000Source | 1,133,000Source | 435,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | 1,500,000Source | 2,215,000Source | 747,000Source | 378,000Source | 445,000Source | 1,500,000Source | 2,215,000Source | 747,000Source | 512,000Source |
| Other Assets, NoncurrentUSD | — | — | — | 486,000Source | 405,000Source | 487,000Source | 236,000Source | 101,000Source | 486,000Source | 405,000Source | 487,000Source | 107,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | — | — | — | 59,941,000Source | 50,433,000Source | 22,712,000Source | 3,449,000Source | 4,836,000Source | 59,941,000Source | 50,433,000Source | 22,712,000Source | 3,162,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | — | — | — | 74,000Source | 70,000Source | 28,000Source | 142,000Source | 142,000Source | 74,000Source | 70,000Source | 282,000Source | 142,000Source |
| Retained Earnings (Accumulated Deficit)USD | — | — | — | -334,840,000Source | -231,719,000Source | -152,440,000Source | -105,932,000Source | -102,665,000Source | -334,840,000Source | -231,719,000Source | -152,440,000Source | -98,597,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | — | 110,000Source | -51,000Source | — | — | — | 110,000Source | -51,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 284,645,000Source | 229,891,000Source | 118,028,000Source | 207,031,000Source | 290,668,000Source | 75,179,000Source | 54,642,000Source | 57,702,000Source | 207,031,000Source | 290,668,000Source | 75,179,000Source | 61,277,000Source |
| Additional Paid in Capital, Common StockUSD | — | — | — | 541,687,000Source | 522,368,000Source | 227,591,000Source | 160,432,000Source | 160,225,000Source | 541,687,000Source | 522,368,000Source | 227,337,000Source | 159,732,000Source |
| Liabilities and EquityUSD | — | — | — | 266,972,000Source | 341,101,000Source | 97,891,000Source | 58,091,000Source | 62,538,000Source | 266,972,000Source | 341,101,000Source | 97,891,000Source | 64,439,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | — | — | — | 28,679,000Source | 18,230,000Source | 15,664,000Source | 2,676,000Source | 4,001,000Source | 28,679,000Source | 18,230,000Source | 15,664,000Source | 2,266,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | 623,000Source | 957,000Source | 46,000Source | 276,000Source | 272,000Source | 623,000Source | 957,000Source | 46,000Source | 268,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | 1,005,000Source | 1,428,000Source | 780,000Source | 116,000Source | 186,000Source | 1,005,000Source | 1,428,000Source | 780,000Source | 256,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | 1,702,000Source | 2,495,000Source | 4,592,000Source | — | — | 1,702,000Source | 2,495,000Source | 4,592,000Source | — |
| Other Liabilities, NoncurrentUSD | — | — | — | 386,000Source | 55,000Source | 0Source | — | — | 386,000Source | 55,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | 144,700,000Source | 226,900,000Source | — | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 1,702,000Source | 2,495,000Source | 4,592,000Source | — |
| Long-term DebtUSD | — | — | — | — | — | — | — | — | 1,625,000Source | 1,677,000Source | 1,725,000Source | — |
| Short-term InvestmentsUSD | — | — | — | 114,108,000Source | 165,336,000Source | 0Source | 22,764,000Source | 35,123,000Source | 114,108,000Source | 165,336,000Source | 0Source | — |
cash flow · annual statements
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q2 2024 | Q2 2023 | Q1 2023 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | 465,000Source | 8,966,000Source | 5,387,000Source | 3,738,000Source | 1,087,000Source |
| Changes in operating assets and liabilities: | ||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | -395,000Source | -110,000Source | -1,049,000Source | 426,000Source | -405,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | 95,000Source | — | — | -359,000Source | 2,673,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | -793,000Source | -2,097,000Source | -2,651,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | -1,763,000Source | -82,484,000Source | -18,294,000Source | -36,913,000Source | -7,710,000Source |
| Cash flows from investing activities: | ||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | -35,166,000Source | 41,228,000Source | -218,931,000Source | 24,373,000Source | -284,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | 90,000Source | 12,749,000Source | 54,414,000Source | 1,072,000Source | 266,000Source |
| Cash flows from financing activities: | ||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | 28,000Source | 10,305,000Source | 289,385,000Source | 785,000Source | 56,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | -36,901,000Source | -30,951,000Source | 52,160,000Source | -11,755,000Source | -7,938,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 84,000Source | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 30,000Source | — | — | — |
| Additional Financial Items | ||||||||||
| AmortizationUSD | — | — | — | — | — | 6,000Source | — | — | 40,000Source | 41,000Source |
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | 465,000Source | 8,966,000Source | 5,221,000Source | 3,143,000Source | 1,087,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 7,000Source | 7,000Source | 7,000Source | 41,000Source |
| Asset Retirement Obligation, Accretion ExpenseUSD | — | — | — | — | — | 8,000Source | — | — | 35,000Source | 32,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | 144,700,000Source | 226,900,000Source | — | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | — | — | — | 0Source | 0Source | — | — |
| DepreciationUSD | — | — | — | — | — | 68,000Source | — | — | 946,000Source | 248,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | -250,000Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | 0Source | -27,000Source | 0Source | 0Source |
| Gain (Loss) on Disposition of BusinessUSD | — | — | — | — | — | — | 0Source | -59,000Source | -4,170,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | 0Source | -27,000Source | -22,000Source | 0Source |
| General and Administrative ExpenseUSD | — | — | — | — | — | 3,114,000Source | 30,233,000Source | 26,613,000Source | 21,064,000Source | 6,621,000Source |
| GoodwillUSD | — | — | — | 24,062,000Source | 0Source | — | — | 0Source | 24,062,000Source | — |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | 0Source | 24,062,000Source | — | — |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | 10,000,000Source | 0Source | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | -2,000Source | -8,000Source | -17,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | -793,000Source | -2,097,000Source | -2,651,000Source | 0Source |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | 298,000Source | — |
| Investment Income, InterestUSD | — | — | — | — | — | 140,000Source | 8,114,000Source | 10,515,000Source | 934,000Source | 119,000Source |
| Net Income (Loss) Attributable to ParentUSD | -18,177,000Source | -12,284,000Source | -371,000Source | — | — | -4,068,000Source | -103,121,000Source | -79,279,000Source | -46,508,000Source | -7,272,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | -7,272,000Source |
| Nonoperating Income (Expense)USD | — | — | — | — | — | 140,000Source | 9,136,000Source | 10,459,000Source | 835,000Source | 119,000Source |
| Operating ExpensesUSD | — | — | — | — | — | 4,622,000Source | 114,448,000Source | 92,340,000Source | 42,375,000Source | 12,007,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | 79,000Source | 100,000Source | 800,000Source | 97,000Source | 312,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 275,807,000Source | 364,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | 28,000Source | 371,000Source | 1,253,000Source | 554,000Source | 56,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | 1,717,000Source | — | — | 1,434,000Source | 10,795,000Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss) | — | — | — | — | — | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2022 | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 | Q2 2022 | Q1 2023 | Q1 2022 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of RevenueUSD | — | — | — | — | 1,469,000Source | 1,596,000Source | 1,303,000Source | 1,535,000Source | — | — | — | 6,179,000Source |
| Operating Income (Loss)USD | — | — | — | — | -1,376,000Source | -1,635,000Source | -4,208,000Source | -2,274,000Source | -113,564,000Source | -90,886,000Source | -40,941,000Source | -7,391,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -104,428,000Source | -80,427,000Source | -40,106,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -793,000Source | -2,097,000Source | -2,651,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | -18,177,000Source | -12,284,000Source | -371,000Source | -1,347,000Source | -1,604,000Source | -4,068,000Source | -2,243,000Source | -103,121,000Source | -79,279,000Source | -46,508,000Source | -7,272,000Source |
| Earnings Per Share, BasicUSD per share | — | — | — | — | — | — | — | — | -1.4Source | -1.23Source | -0.17Source | -0.05Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | — | — | — | — | — | -1.4Source | -1.23Source | — | — |
| Total Revenue | — | — | — | — | — | — | — | — | — | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | — | — | — | — | — | 73,813,000Source | 64,425,000Source | 267,643,000Source | 141,987,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | — | — | — | — | — | 73,813,000Source | 64,425,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 7,000Source | 7,000Source | 7,000Source | 41,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | 3,251,000Source | 2,306,000Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | -250,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | — | — | 1,581,000Source | 1,618,000Source | 3,114,000Source | 1,840,000Source | 30,233,000Source | 26,613,000Source | 21,064,000Source | 6,621,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 24,062,000Source | — | — |
| Gross ProfitUSD | — | — | — | — | 1,441,000Source | 1,220,000Source | 414,000Source | 1,029,000Source | — | — | 1,434,000Source | 4,616,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -104,428,000Source | -79,989,000Source | — | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | — | — | — | — | — | — | -1.41Source | -1.22Source | -0.14Source | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | — | — | — | — | — | — | -1.41Source | -1.22Source | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | -2,000Source | -8,000Source | -17,000Source | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 84,000Source | — |
| Investment Income, InterestUSD | — | — | — | — | 29,000Source | 31,000Source | 140,000Source | 31,000Source | 8,114,000Source | 10,515,000Source | 934,000Source | 119,000Source |
| Marketing and Advertising ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 129,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | -1,347,000Source | -1,604,000Source | — | -2,243,000Source | — | — | — | -7,272,000Source |
| Nonoperating Income (Expense)USD | — | — | — | — | 29,000Source | 31,000Source | 140,000Source | 31,000Source | 9,136,000Source | 10,459,000Source | 835,000Source | 119,000Source |
| Operating ExpensesUSD | — | — | — | — | 2,817,000Source | 2,855,000Source | 4,622,000Source | 3,303,000Source | 114,448,000Source | 92,340,000Source | 42,375,000Source | 12,007,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | 78,000Source | 79,000Source | 79,000Source | 78,000Source | 100,000Source | 800,000Source | 97,000Source | 312,000Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | — | — | 0Source | 0Source | — | 0Source | — | — | — | 0Source |
| Research and Development ExpenseUSD | — | — | — | — | 549,000Source | 535,000Source | 708,000Source | 702,000Source | 84,215,000Source | 41,638,000Source | 21,311,000Source | 2,582,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | 2,910,000Source | 2,816,000Source | 1,717,000Source | 2,564,000Source | — | — | 1,434,000Source | 10,795,000Source |
| Selling and Marketing ExpenseUSD | — | — | — | — | 687,000Source | 702,000Source | 800,000Source | 761,000Source | — | — | — | 2,804,000Source |
Filing attachments
catx-ex99_1.htm · 8-K · 2026-11-09
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results • Updated interim data from the Phase 1/2a bamzireotide navoxetan (VMT-α-NET) presentations continue to support an emerging therapeutic window and potential to achieve a best-in-class profile in NETs • Meaningful antitumor activity observed for lapemelanotide zapixetar (VMT01) monotherapy in metastatic melanoma to be evaluated with additional patients • PSV359 received Fast Track Designation from the FDA…
Read attachment ↗catx-ex99_2.htm · 8-K · 2026-11-09
Next-Generation Radiopharmaceuticals Redefining Targeted Oncology Designed to be the Most Potent Payload in Targeted Oncology Three Independent Clinical-Stage Programs, Each Against a Distinct Target with Data in 2027 Deep Leadership Across Radiopharmaceutical and Drug Development The Perspective Story in Four Parts Radiopharmaceutical Therapy: A Category Still Early in Its Adoption Curve Targeted Delivery of Payloads is Transforming Oncology Therapy $45 Billion+ Addressable Market, Alre…
Read attachment ↗catx-ex99_1.htm · 8-K · 2026-11-06
Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026 • Meaningful antitumor activity observed at the 3.0 mCi monotherapy dose with 75% disease control rate and durable disease stabilization; one of two confirmed responders remains on study ~40 weeks after the first treatment • No dose-limiting toxicities, treatment-related serious adverse events, or discontinuat…
Read attachment ↗catx-ex99_2.htm · 8-K · 2026-11-06
A Phase I/IIa Trial of [212Pb]VMT01 MC1R-targeted Alpha-Particle Mono- and Combination-Therapy with Nivolumab in Participants with Previously Treated Unresectable or Metastatic Melanoma M.S. Block1, Z.S. Morris2, J. Lutzky3, R.L. Wahl4, A.J. Olszanski5, Y. Menda6, S. Mehr7, L. Baratto8, S. Ayuk8, D. Pomponio8, S. Patel8, M. Puhlmann8, R.B. Patel9, and R. Arays10 1Mayo Clinic, Rochester, MN; 2University of Wisconsin, Madison, WI; 3University of Miami, Miami, FL; 4Washington University School of …
Read attachment ↗catx-ex99_1.htm · 8-K · 2026-11-06
Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs • Additional analyses presented at NANETS 2026 Multidisciplinary NET Medical Symposium support prior findings of durable ongoing disease control and encouraging responses in all three cohorts across multiple patient populations • Preliminary evidence of more robust anti-tumor activity and durable responses in GEP-NET pa…
Read attachment ↗catx-ex99_1.htm · 8-K · 2026-10-23
Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs • Results presented at ESMO show a promising therapeutic index for [212Pb]VMT-α-NET • Durable disease control in all three cohorts and 72% PFS at 18 months across all patients who received at least one treatment • Robust activity observed at three dose levels across patient…
Read attachment ↗